High potential of loading various types of active ingredients (proteins, peptides, small molecules, mRNA) on several applications (therapeutic and prophylactic vaccination, precision therapies, etc.)
Custom and specific cell-targeting capacities. Limited risk of pre-existing antibodies against the plant-based nanoparticle
Good safety profile
Human pathogen-free plant-based bioproduction
Limited risk of off-target effects
Modularity
Quality by Design – Custom of therapeutic candidates maximizes chance of success in clinical development
Thermostability
Minimized risk of degradation during storage and transportation
A modular immunization system for enhancing
peptide-based cancer vaccines
The concept
For the therapeutic vaccination market in oncology, the technology is adapted into an effective nanoparticle immunization platform. By targeting the most efficient antigen-presenting immune cells and delivering tumor antigens to them, the platform is able to induce strong specific immune responses against the tumor. In vitro and in vivo results demonstrate the concept.
One step of expression and assembly in plants allows a fast, human pathogens-free and cost-effective production.